The aim of this review was to summarize existing data on the contribution of Vitamin D level and/or deficiency/insufficiency to systemic sclerosis susceptibility and its clinical features.
Methods:
An electronic literature search for eligible studies among all papers published prior to 30 June 2024 was conducted through PubMed, EMBASE, Web of science, and Scopus databases. Meta-analyses estimating pooled raw mean differences, odds ratios, and Pearson r together with subgroup analyses and meta-regressions were performed for the association of Vitamin D with susceptibility to systemic sclerosis and disease presentation.
Results:
Combined analysis revealed a significant decrease in Vitamin D level in systemic sclerosis patients comparatively to healthy controls, with raw mean differences 95% CI = −11.68 [−15.43 to −7.92] ng/mL, p < 1 E-10. Likewise, Vitamin D insufficiency (Vitamin D < 30 ng/mL) and deficiency (<10 ng/mL) were significantly associated with systemic sclerosis; odds ratios 95% CI = 3.58 [2.59–4.95], p < 1 E-10 and odds ratios 95% CI = 7.67 [3.97–14.83], p < 1 E-10, respectively. Moreover, decreased Vitamin D level was significantly associated with interstitial lung disease occurrence (raw mean differences 95% CI = −3.61 [−6.93 to −0.3], p = 0.003), while Vitamin D deficiency was associated with increased systolic pulmonary arterial pressure, raw mean differences (95% CI = 4.17 [1.44–6.89], p = 0.003). Besides, Vitamin D level was negatively correlated with the modified Rodnan skin score, r (95% CI = −0.26 [−0.44 to −0.08], p = 0.004). Conversely, Vitamin D level was significantly increased in systemic sclerosis patients with cutaneous calcinosis, raw mean differences (95% CI = 4.18 [1.07–7.28], p = 0.008).
Conclusion:
This meta-analysis showed that decreased Vitamin D level was associated with susceptibility to systemic sclerosis, interstitial lung disease occurrence, increased systolic pulmonary arterial pressure, and higher modified Rodnan skin score. Conversely, calcinosis was found to be associated with increased Vitamin D level.
Bellando-RandoneSMatucci-CerinicM.Very Early systemic sclerosis and pre-systemic sclerosis: definition, recognition, clinical relevance and future directions. Curr Rheumatol Rep2017; 19(10): 65.
2.
Matucci-CerinicMKahalehBWigleyFM.Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum2013; 65(8): 1953–1962.
3.
RosendahlAHSchönbornKKriegT.Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci2022; 38(3): 187–195.
4.
BenfaremoDSvegliatiSPaoliniC, et al. Systemic sclerosis: from pathophysiology to novel therapeutic approaches. Biomedicines2022; 10(1): 163.
5.
RezaeiRAslaniSDashtiN, et al. Genetic implications in the pathogenesis of systemic sclerosis. Int J Rheum Dis2018; 21(8): 1478–1486.
6.
AlahmariHAhmadZJohnsonSR.Environmental risks for systemic sclerosis. Rheum Dis Clin North Am2022; 48(4): 845–860.
7.
SchneiderLHaxVMonticieloO, et al. Dualities of the vitamin D in systemic sclerosis: a systematic literature review. Adv Rheumatol2021; 61(1): 34.
8.
PerazziMGallinaEManfrediGF, et al. Vitamin D in systemic sclerosis: a review. Nutrients2022; 14(19): 3908.
9.
DiaconuADOstafieICeasovschihA, et al. Role of Vitamin D in systemic sclerosis: a systematic literature review. J Immunol Res2021; 2021: 9782994.
10.
McLeroyKRNorthridgeMEBalcazarH, et al. Reporting guidelines and the American Journal of Public Health’s adoption of preferred reporting items for systematic reviews and meta-analyses. Am J Public Health2012; 102(5): 780–784.
11.
van den HoogenFKhannaDFransenJ, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis2013; 72(11): 1747–1755.
12.
LeRoyECBlackCFleischmajerR, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol1988; 15(2): 202–205.
13.
KahalehMBSultanyGLSmithEA, et al. A modified scleroderma skin scoring method. Clin Exp Rheumatol1986; 4(4): 367–369.
BorensteinMHedgesLVHigginsJP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods2010; 1(2): 97–111.
16.
AhmadiRHajialiloMGhorbanihaghjoA, et al. FGF-23, Klotho and Vitamin D Levels in scleroderma. Iran J Public Health2017; 46(4): 530–536.
17.
ArnsonYAmitalHAgmon-LevinN, et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev2011; 10(8): 490–494.
18.
AtteritanoMSorbaraSBagnatoG, et al. Bone mineral density, bone turnover markers and fractures in patients with systemic sclerosis: a case control study. PLoS ONE2013; 8(6): e66991.
19.
AtteritanoMSantoroDCoralloG, et al. Skin involvement and pulmonary hypertension are associated with Vitamin D insufficiency in scleroderma. Int J Mol Sci2016; 17(12): 2103.
20.
CaimmiCBertoldoEPozzaA, et al. Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: A longitudinal study. Int J Rheum Dis2019; 22(6): 1041–1045.
21.
CalzolariGDataVCarignolaR, et al. Hypovitaminosis D in systemic sclerosis. J Rheumatol2009; 36(12): 2844.
22.
CaramaschiPDalla GassaARuzzenenteO, et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol2010; 29(12): 1419–1425.
23.
CoralloCFioravantiATentiS, et al. Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features. Rheumatol Int2019; 39(10): 1767–1775.
24.
CorradoAColiaRMeleA, et al. Relationship between body mass composition, bone mineral density, skin fibrosis and 25(OH) Vitamin D serum levels in systemic sclerosis. PLoS ONE2015; 10(9): e0137912.
25.
CorradoARotondoCSanpaoloER, et al. 1,25OH-Vitamin D3 and IL-17 inhibition modulate pro-fibrotic cytokines production in peripheral blood mononuclear cells of patients with systemic sclerosis. Int J Med Sci2022; 19(5): 867–877.
26.
Cruz-DomínguezMPGarcía-CollinotGSaavedraMA, et al. Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis. Clin Rheumatol2017; 36(1): 111–117.
27.
EceSMahmutMSNeslihanG, et al. Hypovitaminosis D in patients with systemic sclerosis: Evaluating the role of skin involvement. J Turk Soc Rheumatol2023; 15(3): 106–112.
28.
El GharbawyNHShehaDSBawadySA, et al. Vascular endothelial growth factor profile and Vitamin D level in systemic sclerosis Egyptian patients. Egypt J Immunol2021; 28(3): 168–175.
29.
GroseanuLBojincaVGuduT, et al. Low vitamin D status in systemic sclerosis and the impact on disease phenotype. Eur J Rheumatol2016; 3(2): 50–55.
30.
GuptaSMahajanVKYadavRS, et al. Evaluation of serum Vitamin D levels in patients with systemic sclerosis and healthy controls: Results of a pilot study. Indian Dermatol Online J2018; 9(4): 250–255.
31.
HajialiloMNoorabadiPTahsini TekantapehS, et al. Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients. Rheumatol Int2017; 37(10): 1651–1657.
32.
HaxVGasparinAASchneiderL, et al. Vitamin D and cytokine profiles in patients with systemic sclerosis. J Clin Rheumatol2020; 26(7): 289–294.
33.
HorváthÁVéghEPusztaiA, et al. Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients. Arthritis Res Ther2019; 21(1): 274.
34.
Ibn YacoubYAmineBLaatirisA, et al. Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status. Rheumatol Int2012; 32(10): 3143–3148.
35.
IsolaGPalazzoGPolizziA, et al. Association of systemic sclerosis and periodontitis with Vitamin D levels. Nutrients2021; 13(2): 705.
36.
JudPMeinitzerAStrohmaierH, et al. Association of amino acids and parameters of bone metabolism with endothelial dysfunction and vasculopathic changes in limited systemic sclerosis. Front Med2023; 10: 1193121.
37.
KotylaPJKruszec-ZytniewskaAOwczarekAJ, et al. Fibroblast growth factor 23 to Alpha-Klotho index correlates with systemic sclerosis activity: A proposal for novel disease activity marker. J Clin Med2018; 7(12): 558.
38.
LeeKAKimHJKimHS.Comparison of predictive value of FRAX, trabecular bone score, and bone mineral density for vertebral fractures in systemic sclerosis: A cross-sectional study. Medicine2023; 102(2): e32580.
39.
Lo GulloAMandraffinoGRodríguez-CarrioJ, et al. Endocan and circulating progenitor cells in women with systemic sclerosis: Association with inflammation and pulmonary hypertension. Biomedicines2021; 9(5): 533.
40.
MontaboneEDataVCarignolaR.Vitamin D status and quality of life in systemic sclerosis patients. J Clin Rheumatol2016; 22(4): 229–230.
41.
OmelchenkoLIMukvichOMIsmakaevaDL, et al. Concentration of 25(OH)D in blood serum and certain aspects of the clinical course of juvenile scleroderma. Ukrain J Perinatol Pediatr2021(87): 44–50.
42.
OrbachHZandman-GoddardGAmitalH, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci2007; 1109: 385–400.
43.
ParkEKParkJHKweonSM, et al. Vitamin D deficiency is associated with digital ulcer but not with atherosclerosis or arterial stiffness in patients with systemic sclerosis: a pilot study. Clin Rheumatol2017; 36(6): 1325–1333.
44.
Sampaio-BarrosMMTakayamaLSampaio-BarrosPD, et al. Low vitamin D serum levels in diffuse systemic sclerosis: a correlation with worst quality of life and severe capillaroscopic findings. Rev Bras Reumatol Engl Ed2016; 56(4): 337–344.
45.
Sampaio-BarrosMMCastelo BrancoLCMTakayamaL, et al. Acroosteolysis and bone metabolism parameters distinguish female patients with limited systemic sclerosis with and without calcinosis: a case control study. Clin Rheumatol2019; 38(11): 3189–3193.
46.
SerioloBMolfettaLCutoloM.Seasonal variations in serum levels of 25-hydroxyvitamin D in patients with systemic sclerosis. Clin Rheumatol2011; 30(3): 445–446.
47.
SerupJHagdrupH.Vitamin D metabolites in generalized scleroderma. Acta Derm Venereol1985; 65(4): 343–345.
48.
ShinjoSKBonfáEde Falco CaparboV, et al. Low bone mass in juvenile onset sclerosis systemic: the possible role for 25-hydroxyvitamin D insufficiency. Rheumatol Int2011; 31(8): 1075–1080.
49.
SirufoMMDe PietroFRaggiuntiM, et al. AB0434 Vitamin D in systemic sclerosis patients. Ann Rheum Dis2021; 80: 1246.
50.
TaylanABirlikMKenarG, et al. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and WNT inhibitors. Mod Rheumatol2019; 29(4): 619–624.
51.
TrombettaACSmithVGotelliE, et al. Vitamin D deficiency and clinical correlations in systemic sclerosis patients: A retrospective analysis for possible future developments. PLoS ONE2017; 12(6): e0179062.
52.
UrsiniFD’AngeloSPadulaA, et al. Vitamin D deficiency in systemic sclerosis: a possible role of subclinical liver fibrosis? Retrospective analysis from an Italian cohort. Clin Rheumatol2017; 36(12): 2871–2872.
53.
ŻebrykPNowakJKPiorunekT, et al. 25-hydroxyvitamin D3 levels and their clinical associations in a polish cohort of systemic sclerosis patients: a cross-sectional study. Applied Sciences2022; 12(1): 265.
54.
ZhangLDuanYZhangTP, et al. Association between the serum level of vitamin D and systemic sclerosis in a Chinese population: a case control study. Int J Rheum Dis2017; 20(8): 1002–1008.
55.
IslamMAKhandkerSSAlamSS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Autoimmun Rev2019; 18(11): 102392.
56.
LeeYHBaeSC.Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clin Exp Rheumatol2016; 34(5): 827–833.
57.
DuanSLvZFanX, et al. Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis. Neurosci Lett2014; 570: 108–113.
58.
IrfanSAAliAAShabbirN, et al. Effects of Vitamin D on systemic lupus erythematosus disease activity and autoimmunity: a systematic review and meta-analysis. Cureus2022; 14(6): e25896.
59.
KuoCYHuangYCLinKJ, et al. Vitamin D deficiency is associated with severity of dry eye symptoms and primary Sjögren’s syndrome: a systematic review and meta-analysis. J Nutr Sci Vitaminol2020; 66(4): 386–388.
60.
Martínez-LapiscinaEHMahatananRLeeCH, et al. Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. J Neurol Sci2020; 411: 116668.
61.
AnLSunMHChenF, et al. Vitamin D levels in systemic sclerosis patients: a meta-analysis. Drug Des Devel Ther2017; 11: 3119–3125.
62.
AltmanDGRoystonP.The cost of dichotomising continuous variables. BMJ2006; 332(7549): 1080.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
